Male and female participants ≥18 years of age and at least at the legal age of consent
You may not be if
At least one measurable lesion outside of central nervous system (CNS) as defined per modified Response Evaluation Criteria In Solid Tumors (RECIST) v1.1
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
Life expectancy ≥3 months at the start of treatment in the opinion of the investigator
Patients with known brain metastases are eligible, provided they meet the protocol-defined criteria
Previous or concomitant malignancies other than the one treated in this trial within the past 3 years (except effectively treated malignancy considered cured by local treatment, e.g. non melanoma skin cancers, carcinoma in situ of the cervix, ductal carcinoma in situ)
Patient with known leptomeningeal disease or spinal cord compression due to disease
Patients with hepatitis C infection or active hepatitis B infection (chronic or acute)
Patients with known history of Human immunodeficiency virus (HIV) infection who meet protocol-defined criteria
Patient with active autoimmune disease or a documented history of autoimmune disease, which requires systemic treatment (e.g. corticosteroids or immunosuppressive drugs)
Patient with a diagnosis of immunodeficiency other than HIV
